The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 4, 2007, Pages 1249-1255

  Balas, Bogdan ^a,g   Baig, Muhammad R ^a   Watson, Catherine ^b   Dunning, Beth E ^c   Ligueros Saylan, Monica ^d   Wang, Yibin ^d   He, Yan Ling ^b   Darland, Celia ^a   Holst, Jens J ^e   Deacon, Carolyn F ^e   Cusi, Kenneth ^a   Mari, Andrea ^f   Foley, James E ^d   DeFronzo, Ralph A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NicheUSA LLC   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f CNR   (Italy)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; TRITIUM; VILDAGLIPTIN;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TEST MEAL;

EID: 34147189738     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1882     Document Type: Article

References (23)

1. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE 2003 1-[[(3-Hydroxy-1-adamantyl)amino] acetyl]2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774-2789
2. Dardik B, Valentin M, Schwartzkopf C, Gutierrez C, Stevens D, Russel M, Villhauer E, Hughes T 2003 NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant cynomolgus monkeys. Diabetes 52(Suppl 1):A322
3. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A 2004 Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084
4. Ahren B, Gomis R, Standl E, Mills D, Schweizer A 2004 Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880
5. Kreymann B, Williams G, Ghatei MA, Bloom SR 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304
6. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH 2002 Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87:1239-1246
7. Nauck MA, El-Ouaghlidi A 2005 The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 48:608-611
8. Holst JJ, Deacon CF 2005 Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48:612-615
9. Ahren B, Pacini G, Foley JE, Schweizer A 2005 Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28:1936-1940
10. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE 2005 Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894
11. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR 2005 Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 315:688-695
12. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA 1989 Glucose and free fatty acid metabolism in non-insulindependent diabetes mellitus. evidence for multiple sites of insulin resistance. J Clin Invest 84:205-213
13. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ 2000 Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581
14. Radziuk J, Norwich KH, Vranic M 1978 Experimental validation of measurements of glucose turnover in nonsteady state. Am J Physiol 234:E84-E93
15. Ferrannini E, Simonson DC, Katz LD, Reichard Jr G, Bevilacqua S, Barrett EJ, Olsson M, DeFronzo RA 1988 The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism 37:79-85
16. Van Cauter E, Mestrez F, Sturis J, Polonsky KS 1992 Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368-377
17. Hovorka R, Soons PA, Young MA 1996 ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 50:253-264
18. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E 2002 Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159-E1166
19. Mari A, Tura A, Gastaldelli A, Ferrannini E 2002 Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51(Suppl 1):S221-S226
20. Meyer C, Woerle HJ, Dostou JM, Welle SL, Gerich JE 2004 Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab 287:E1049-E1056
21. Prigeon RL, Quddusi S, Paty B, D'Alessio DA 2003 Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285:E701-E707
22. DeFronzo RA, Ferrannini E, Simonson DC 1989 Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387-395
23. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C 2004 Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89:3055-3061